Advanced Search
Contact | Corporate | Help

A Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-Sponsored Phase I or II Cancer Study

Sponsors:
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Basal Cell Carcinoma
  • Metastatic Colorectal Cancer
  • Ovarian Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: bevacizumab
  • Drug: FOLFIRI
  • Drug: FOLFOX
  • Drug: GDC-0449
Enrollment:
250

Additional information about NCT00959647.


SourceSolution © 2008-2012